CARBAMAZEPINE AND LITHIUM TREATMENT OF BIPOLAR ILLNESS

卡马西平和锂盐治疗双相情感障碍

• 批准号: 3881000
• 负责人: R M POST
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3881000
• 关键词: bipolar depression; carbamazepine; clinical trials; combination chemotherapy; human subject; human therapy evaluation; lithium; mental disorder chemotherapy

We are studying and comparing the prophylactic therapeutic effects of lithium with carbamazepine in a double-blind, randomized, crossover design followed by a period of treatment with both drugs in combination, in outpatients with manic-depressive illness. We intend to further explore the possible differential clinical efficacy of lithium, carbamazepine, and the combination, and assess possible clinical and biological correlates of response. We now have 36 patients (27 of whom have entered the randomized drug trial) and plan to recruit a total of 50 patients. Each patient will have the following tests: blood count, thyroid functions, SMAC, 24-hour urine collection for urinary free cortisol and neurotransmitter metabolites, TRH stimulation, DST, lumbar puncture, EEG, MRI, EKG, and an extensive battery of neuropsychological tests. Patients have an extensive history taken, a life chart constructed, and psychosensory symptoms assessed. A number of self- and observer-ratings are performed. This study is too early in its course (each patient will be studied for three years and the study began in October 1988) to report any results.

我们正在研究和比较 锂与卡马西平的双盲、随机、交叉设计 然后用两种药物联合治疗一段时间， 患有躁狂抑郁症的门诊病人。我们打算进一步探讨 锂盐、卡马西平和 组合，并评估可能的临床和生物学相关性， 反应我们现在有36例患者（其中27例已进入随机对照组）， 药物试验），并计划招募共50名患者。每例患者将 有以下测试：血细胞计数，甲状腺功能，SMAC，24小时 尿游离皮质醇和神经递质采集 代谢物、TRH刺激、DST、腰椎穿刺、EEG、MRI、EKG和 大量的神经心理测试患者有广泛的 记录病史，绘制生命图表，以及心理感觉症状 评估。进行了许多自我和自我评价。本研究 在其过程中还为时过早（每个患者将被研究三年 该研究于1988年10月开始），以报告任何结果。